Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Apexbio Technology LLC MGCD-265 875337-44-3 10mM (in 1mL DMSO)
Supplier: Apexbio Technology LLC A50575.1
MGCD-265 (CAS 875337-44-3) is a multi-targeted ATP-competitive small molecule inhibitor primarily targeting c-Met and the vascular endothelial growth factor receptors VEGFR1 VEGFR2 and VEGFR3 with IC50 values of 1 nM 3 nM 3 nM and 4 nM respectively In preclinical non-small cell lung cancer (NSCLC) xenograft models including models with TKI-resistant EGFR T790M mutations MGCD-265 in combination with agents such as paclitaxel docetaxel or erlotinib demonstrated enhanced antitumor activity and antiangiogenic effects compared to monotherapy MGCD-265 has been investigated in phase I clinical trials as a single agent and in combination with docetaxel or erlotinib in patients with advanced solid tumors
Product Title
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.
Spot an opportunity for improvement?